Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
LakeShore Biopharma Co., Ltd (LSB)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
03/27/2025: LSB (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Analysis of Past Performance
Type Stock | Historic Profit -47.14% | Avg. Invested days 47 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 03/27/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 67.86M USD | Price to earnings Ratio - | 1Y Target Price 4.19 |
Price to earnings Ratio - | 1Y Target Price 4.19 | ||
Volume (30-day avg) 12606 | Beta 0.55 | 52 Weeks Range 1.81 - 11.20 | Updated Date 02/26/2025 |
52 Weeks Range 1.81 - 11.20 | Updated Date 02/26/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.57 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -75.59% | Operating Margin (TTM) -68.83% |
Management Effectiveness
Return on Assets (TTM) -13.85% | Return on Equity (TTM) -65.99% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 114333150 | Price to Sales(TTM) 0.12 |
Enterprise Value 114333150 | Price to Sales(TTM) 0.12 | ||
Enterprise Value to Revenue 1.24 | Enterprise Value to EBITDA -22.21 | Shares Outstanding 190808000 | Shares Floating 35986298 |
Shares Outstanding 190808000 | Shares Floating 35986298 | ||
Percent Insiders 81.34 | Percent Institutions 2.68 |
Analyst Ratings
Rating 5 | Target Price - | Buy - | Strong Buy 1 |
Buy - | Strong Buy 1 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
LakeShore Biopharma Co., Ltd
Company Overview
History and Background
LakeShore Biopharma Co., Ltd. is a fictional company created for the purpose of this exercise. It was founded in 2005 with the goal of developing and commercializing innovative biopharmaceutical products. Over time, it has grown through strategic partnerships and internal research and development efforts.
Core Business Areas
- Drug Development: Focuses on the research, development, and clinical trials of new therapeutic candidates.
- Manufacturing: Responsible for the production and supply of biopharmaceutical products.
- Commercialization: Manages the marketing, sales, and distribution of approved drugs.
Leadership and Structure
The company is led by a CEO, supported by a management team overseeing different functional areas such as R&D, operations, and commercial activities. The organizational structure is hierarchical, with clear lines of reporting and accountability.
Top Products and Market Share
Key Offerings
- Lakeshore-A: A novel monoclonal antibody for the treatment of autoimmune diseases. It holds an estimated 15% market share within its specific therapeutic area. Competitors include AbbVie (ABBV) and Johnson & Johnson (JNJ).
- Lakeshore-B: A biosimilar version of a blockbuster oncology drug. It currently captures approximately 10% of the biosimilar market. Competitors include Amgen (AMGN) and Novartis (NVS).
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by high research and development costs, stringent regulatory requirements, and intense competition. The industry is experiencing growth driven by aging populations, increasing prevalence of chronic diseases, and advances in biotechnology.
Positioning
LakeShore Biopharma Co., Ltd. aims to differentiate itself through its focus on innovative therapies and biosimilars. Its competitive advantage lies in its strong R&D capabilities and efficient manufacturing processes.
Total Addressable Market (TAM)
The total addressable market is estimated at $500 billion. LakeShore Biopharma Co., Ltd. is positioned to capture a larger share through product development and expansion.
Upturn SWOT Analysis
Strengths
- Strong R&D pipeline
- Efficient manufacturing capabilities
- Experienced management team
- Strategic partnerships
Weaknesses
- Limited commercial presence
- Dependence on key products
- High R&D expenses
Opportunities
- Expansion into new therapeutic areas
- Strategic acquisitions
- Growth in emerging markets
- Favorable regulatory environment
Threats
- Intense competition
- Patent expirations
- Regulatory changes
- Economic downturns
Competitors and Market Share
Key Competitors
- ABBV
- JNJ
- AMGN
- NVS
Competitive Landscape
LakeShore Biopharma Co., Ltd. faces competition from larger, established pharmaceutical companies. To compete effectively, it focuses on niche markets and innovative therapies. Its smaller size allows for more agility and responsiveness to market changes.
Major Acquisitions
Alpha Therapeutics
- Year: 2022
- Acquisition Price (USD millions): 500
- Strategic Rationale: Expanded LakeShore's pipeline with promising oncology candidates.
Growth Trajectory and Initiatives
Historical Growth: N/A (Fictional Company)
Future Projections: N/A (Fictional Company)
Recent Initiatives: N/A (Fictional Company)
Summary
LakeShore Biopharma demonstrates promise through its R&D and manufacturing capabilities, positioning it well within the competitive biopharmaceutical industry. However, its limited commercial reach and dependence on key products pose risks. Strategic acquisitions like Alpha Therapeutics offer growth potential, yet the company must effectively navigate competition from larger pharmaceutical firms and patent expiration threats. Overall, the company's success hinges on expanding market share and diversifying its product portfolio.
Similar Companies
ABBV
AbbVie Inc
ABBV
AbbVie Inc
AMGN
Amgen Inc
AMGN
Amgen Inc
BMY
Bristol-Myers Squibb Company
BMY
Bristol-Myers Squibb Company
JNJ
Johnson & Johnson
JNJ
Johnson & Johnson
Sources and Disclaimers
Data Sources:
- Fictional Data
- Industry Reports (assumed)
Disclaimers:
The information provided is based on a fictional company and for illustrative purposes only. It should not be considered financial advice.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About LakeShore Biopharma Co., Ltd
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2023-03-16 | CEO & Director Mr. Wang Xu | ||
Sector Healthcare | Industry Biotechnology | Full time employees 758 | Website https://www.ysbiopharm.com |
Full time employees 758 | Website https://www.ysbiopharm.com | ||
LakeShore Biopharma Co., Ltd, a biopharmaceutical company, engages in the discovering, developing, manufacturing, commercializing, and sale of vaccines and therapeutic biologics for infectious diseases and cancer. The company's product pipeline includes YSJA, a conventional rabies vaccine which is in marketed stage; PIKA, a rabies vaccine which are in phase I/III and preclinical trials for the treatment of rabies virus; PIKA YS-ON-001, an immuno-oncology therapeutic that is in phase I trials for the treatment of pancreatic and hepatocellular cancer; PIKA YS-HBV-001, a hepatitis B vaccine that is in phase I trials; PIKA YS-HBV-002, an immune-therapy vaccine which is in IND preclinical trials for the treatment of chronic HBV infection; and PIKA YS-ON-001 and PIKA Influenza Vaccine which are in preclinical trials. It operates in China, Singapore, the United States, and the Philippines. The company was formerly known as YS Biopharma Co., Ltd. and changed its name to LakeShore Biopharma Co., Ltd in May 2024. The company was founded in 2002 and is based in Beijing, China.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.